risks of glp 1 injections BMI & the Role Semaglutide GLP-1 in Weight Loss GLP-1 Weight-Loss Injections May Pose

A new mild symptom after a dose step is normal

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) are approved for type 2 diabetes and obesity, not Hashimoto's thyroiditis

Our team's internal testing underscores this

Theyre meant to fill in the gaps when commercial products are not appropriate or available, Shabbir Imber Safdar, executive director of the San Francisco-based Partnership for Safe Medicines, told IBJ

However, response may vary: Higher baseline weight Individuals starting at higher body weights may experience: Slower percentage weight loss initially Need for full maintenance doses to achieve optimal effects Potentially better tolerance of higher doses Lower baseline weight Those with lower starting weights might: Achieve therapeutic goals at submaximal doses (e.g., 2.4 mg vs